# This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

> **NCT05061940** · — · TERMINATED · sponsor: **Repertoire Immune Medicines** · enrollment: 22 (actual)

## Conditions studied

- Head and Neck Cancer
- Melanoma
- HPV-Related Malignancy
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Lung Cancer, Nonsmall Cell
- Melanoma (Skin)

## Interventions

- **DIAGNOSTIC_TEST:** Tumor Profiling

## Key facts

- **NCT ID:** NCT05061940
- **Lead sponsor:** Repertoire Immune Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-05
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Development program terminated
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061940, "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05061940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*